Biotage AB (Sweden) Performance
| BIOT Stock | SEK 152.30 0.50 0.33% |
The firm shows a Beta (market volatility) of 0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biotage AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biotage AB is expected to be smaller as well. At this point, Biotage AB has a negative expected return of -0.37%. Please make sure to confirm Biotage AB's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Biotage AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biotage AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 371 M | |
| Total Cashflows From Investing Activities | -341 M |
Biotage |
Biotage AB Relative Risk vs. Return Landscape
If you would invest 19,670 in Biotage AB on September 1, 2024 and sell it today you would lose (4,440) from holding Biotage AB or give up 22.57% of portfolio value over 90 days. Biotage AB is generating negative expected returns and assumes 1.9961% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Biotage, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biotage AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotage AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biotage AB, and traders can use it to determine the average amount a Biotage AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1839
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIOT |
Estimated Market Risk
| 2.0 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biotage AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotage AB by adding Biotage AB to a well-diversified portfolio.
Biotage AB Fundamentals Growth
Biotage Stock prices reflect investors' perceptions of the future prospects and financial health of Biotage AB, and Biotage AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotage Stock performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 12.84 B | |||
| Shares Outstanding | 65.98 M | |||
| Price To Earning | 38.27 X | |||
| Price To Book | 8.12 X | |||
| Price To Sales | 8.04 X | |||
| Revenue | 1.23 B | |||
| EBITDA | 347 M | |||
| Cash And Equivalents | 311 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 180 M | |||
| Debt To Equity | 26.40 % | |||
| Book Value Per Share | 24.23 X | |||
| Cash Flow From Operations | 353 M | |||
| Earnings Per Share | 3.73 X | |||
| Total Asset | 1.99 B | |||
| Retained Earnings | 541 M | |||
| Current Asset | 327 M | |||
| Current Liabilities | 115 M | |||
About Biotage AB Performance
Assessing Biotage AB's fundamental ratios provides investors with valuable insights into Biotage AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biotage AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Biotage AB , a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions and commercial, hospitalbio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. Biotage AB operates under Medical Instruments Supplies classification in Sweden and is traded on Stockholm Stock Exchange. It employs 438 people.Things to note about Biotage AB performance evaluation
Checking the ongoing alerts about Biotage AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biotage AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotage AB generated a negative expected return over the last 90 days | |
| About 65.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Biotage AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotage AB's stock is overvalued or undervalued compared to its peers.
- Examining Biotage AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotage AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotage AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotage AB's stock. These opinions can provide insight into Biotage AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biotage Stock Analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.